Targeting mTOR pathways in human malignancies

Angelica Fasolo, Cristiana Sessa

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-Kinase (PI3K)/AKT signalling pathway with a central role in the control of cell growth, survival and angiogenesis. Multiple and frequent dysregulations of this pathway in human tumors make it a central target in the development of new anticancer treatments. Objective: To review the most significant data on mTOR pathway, role of mTOR inhibitors in cancer treatment, preclinical and clinical data of the three first generation mTOR inhibitors (temsirolimus, everolimus and deferolimus), rationales, preclinical and clinical data of second generation mTOR inhibitors. Methods: Review of published literature on mTOR and related pathways, rapalogs and novel mTOR inhibitors. Results/conclusions: Temsirolimus and everolimus have been approved for the treatment of metastatic Renal Cell Carcinoma (RCC), temsirolimus also for Mantle Cell Lymphoma (MCL) and everolimus will be approved for pancreatic neuroendocrine tumors; all three rapalogs are currently evaluated in phase III studies in several tumors. Only limited published data are available on new mTOR inhibitors; however, in vitro and in vivo in preclinical studies they have shown a significant antiproliferative activity against a broad panel of tumors and a favourable safety profile, with disease stabilization or even tumor regression, either as single agent or in combination.

Original languageEnglish
Pages (from-to)2766-2777
Number of pages12
JournalCurrent Pharmaceutical Design
Volume18
Issue number19
Publication statusPublished - Jun 2012

Fingerprint

Sirolimus
Neoplasms
Phosphatidylinositol 3-Kinase
Mantle-Cell Lymphoma
Neuroendocrine Tumors
Renal Cell Carcinoma
Protein Kinases
Cell Survival
Safety
Growth
temsirolimus
Everolimus

Keywords

  • Deforolimus
  • Dual-kinase PI3K/mTOR-inhibitors
  • Everolimus
  • Mammalian target of rapamycin
  • Mantle cell lymphoma
  • mTORC1/mTORC2-inhibitors
  • Renal cell carcinoma
  • Temsirolimus

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Fasolo, A., & Sessa, C. (2012). Targeting mTOR pathways in human malignancies. Current Pharmaceutical Design, 18(19), 2766-2777.

Targeting mTOR pathways in human malignancies. / Fasolo, Angelica; Sessa, Cristiana.

In: Current Pharmaceutical Design, Vol. 18, No. 19, 06.2012, p. 2766-2777.

Research output: Contribution to journalArticle

Fasolo, A & Sessa, C 2012, 'Targeting mTOR pathways in human malignancies', Current Pharmaceutical Design, vol. 18, no. 19, pp. 2766-2777.
Fasolo, Angelica ; Sessa, Cristiana. / Targeting mTOR pathways in human malignancies. In: Current Pharmaceutical Design. 2012 ; Vol. 18, No. 19. pp. 2766-2777.
@article{5cdc1ea992eb4413819dc9a74bd911e6,
title = "Targeting mTOR pathways in human malignancies",
abstract = "Background: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-Kinase (PI3K)/AKT signalling pathway with a central role in the control of cell growth, survival and angiogenesis. Multiple and frequent dysregulations of this pathway in human tumors make it a central target in the development of new anticancer treatments. Objective: To review the most significant data on mTOR pathway, role of mTOR inhibitors in cancer treatment, preclinical and clinical data of the three first generation mTOR inhibitors (temsirolimus, everolimus and deferolimus), rationales, preclinical and clinical data of second generation mTOR inhibitors. Methods: Review of published literature on mTOR and related pathways, rapalogs and novel mTOR inhibitors. Results/conclusions: Temsirolimus and everolimus have been approved for the treatment of metastatic Renal Cell Carcinoma (RCC), temsirolimus also for Mantle Cell Lymphoma (MCL) and everolimus will be approved for pancreatic neuroendocrine tumors; all three rapalogs are currently evaluated in phase III studies in several tumors. Only limited published data are available on new mTOR inhibitors; however, in vitro and in vivo in preclinical studies they have shown a significant antiproliferative activity against a broad panel of tumors and a favourable safety profile, with disease stabilization or even tumor regression, either as single agent or in combination.",
keywords = "Deforolimus, Dual-kinase PI3K/mTOR-inhibitors, Everolimus, Mammalian target of rapamycin, Mantle cell lymphoma, mTORC1/mTORC2-inhibitors, Renal cell carcinoma, Temsirolimus",
author = "Angelica Fasolo and Cristiana Sessa",
year = "2012",
month = "6",
language = "English",
volume = "18",
pages = "2766--2777",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "19",

}

TY - JOUR

T1 - Targeting mTOR pathways in human malignancies

AU - Fasolo, Angelica

AU - Sessa, Cristiana

PY - 2012/6

Y1 - 2012/6

N2 - Background: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-Kinase (PI3K)/AKT signalling pathway with a central role in the control of cell growth, survival and angiogenesis. Multiple and frequent dysregulations of this pathway in human tumors make it a central target in the development of new anticancer treatments. Objective: To review the most significant data on mTOR pathway, role of mTOR inhibitors in cancer treatment, preclinical and clinical data of the three first generation mTOR inhibitors (temsirolimus, everolimus and deferolimus), rationales, preclinical and clinical data of second generation mTOR inhibitors. Methods: Review of published literature on mTOR and related pathways, rapalogs and novel mTOR inhibitors. Results/conclusions: Temsirolimus and everolimus have been approved for the treatment of metastatic Renal Cell Carcinoma (RCC), temsirolimus also for Mantle Cell Lymphoma (MCL) and everolimus will be approved for pancreatic neuroendocrine tumors; all three rapalogs are currently evaluated in phase III studies in several tumors. Only limited published data are available on new mTOR inhibitors; however, in vitro and in vivo in preclinical studies they have shown a significant antiproliferative activity against a broad panel of tumors and a favourable safety profile, with disease stabilization or even tumor regression, either as single agent or in combination.

AB - Background: The mammalian target of rapamycin (mTOR) is a protein kinase involved in the phosphatidylinositol 3-Kinase (PI3K)/AKT signalling pathway with a central role in the control of cell growth, survival and angiogenesis. Multiple and frequent dysregulations of this pathway in human tumors make it a central target in the development of new anticancer treatments. Objective: To review the most significant data on mTOR pathway, role of mTOR inhibitors in cancer treatment, preclinical and clinical data of the three first generation mTOR inhibitors (temsirolimus, everolimus and deferolimus), rationales, preclinical and clinical data of second generation mTOR inhibitors. Methods: Review of published literature on mTOR and related pathways, rapalogs and novel mTOR inhibitors. Results/conclusions: Temsirolimus and everolimus have been approved for the treatment of metastatic Renal Cell Carcinoma (RCC), temsirolimus also for Mantle Cell Lymphoma (MCL) and everolimus will be approved for pancreatic neuroendocrine tumors; all three rapalogs are currently evaluated in phase III studies in several tumors. Only limited published data are available on new mTOR inhibitors; however, in vitro and in vivo in preclinical studies they have shown a significant antiproliferative activity against a broad panel of tumors and a favourable safety profile, with disease stabilization or even tumor regression, either as single agent or in combination.

KW - Deforolimus

KW - Dual-kinase PI3K/mTOR-inhibitors

KW - Everolimus

KW - Mammalian target of rapamycin

KW - Mantle cell lymphoma

KW - mTORC1/mTORC2-inhibitors

KW - Renal cell carcinoma

KW - Temsirolimus

UR - http://www.scopus.com/inward/record.url?scp=84862528335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862528335&partnerID=8YFLogxK

M3 - Article

C2 - 22475451

AN - SCOPUS:84862528335

VL - 18

SP - 2766

EP - 2777

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 19

ER -